Phase 2 Study of ADI PEG 20 in Non-Hodgkins Lymphoma Subjects Who Have Failed Prior Systemic Therapy
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Pegargiminase (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Polaris Pharmaceuticals
- 13 Apr 2016 Status changed from active, no longer recruiting to completed.
- 02 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
- 02 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.